Scailyte, a Basel, Switzerland-based med-tech company, raised CHF6M in Series A funding.
The round was led by a Swiss family office, Mirabaud bank and existing backers.
The company intends to use the funds to accelerate growth, expand operations and its business reach.
Led by Dr. Peter Nestorov, Founder & Chief Executive Officer, Scailyte is a spin-off of ETH Zurich that combines single-cell technologies, high-quality datasets and machine learning methods to identify disease-specific biomarkers, with a focus on oncology and immunology. Its data analysis platform ScaiVision associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, in order to identify ultra-sensitive biomarker signatures.
FinSMEs
01/10/2022